Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: status after Monday 01-Aug meeting review of results domain for MN assay

...

Expand
titlets.xpt (trial summary, study level parameters)
  • Assumption: Study can have more than one assay type
  • Assumption: ASSAYID value of ALL means it applies to all assays in the study

Row

STUDYID

ASSAYID

DOMAIN

TSSEQ

TSGRPID

TSPARMCD

TSPARM

TSVAL

TSVALNF

1123

ALL

TS1
GLPTYPGood Laboratory Practice TypeFDA
11123ALLTS1
STSTDTCStudy Start Date2007-12-30
13123ALLTS1
STITLEStudy TitleExample of a Crossover study in the Rat with 3 dose levels and 3 dosing periods
14123ALLTS1
SNDIGVERSEND Implementation Guide VersionTobacco IMPLEMENTATION GUIDE VERSION 1.0
15123

ALL

TS1
SNDCTVERSEND Controlled Terminology VersionSEND Terminology 2021-03-26
17123ALLTS1
SSPONSORSponsor OrganizationExample Sponsor Inc.
18123ALLTS1
SPREFIDSponsor's Study Reference ID
NOT APPLICABLE
19123ALLTS11TSTFNAMTest Facility NameExample Tox Lab Name
20123

ALL

TS11TSTFLOCTest Facility Location10 Somewhere Street, Montgomery, AL 10000
21123ALLTS11TFCNTRYTest Facility CountryUSA
24123ALLTS11STDIRStudy DirectorDr. R. Smith
25123
TS1
TRTInvestigational Therapy or TreatmentDrug A
26123
TS12TRTVTreatment VehicleSaline
27123
TS12TRTVDESCTreatment Vehicle Structured Description100.46 %(w/v) ISOTONIC SODIUM CHLORIDE SOLUTION {UNII VR5Y7PDT5W}
28123ALLTS1
GLPFLGLP FlagY
29123MNTTS1
ASTDAssay StandardOECD Test No. 487 
30123MNTTS1
ASTDVAssay Standard Version2016-07-29
31123MNTTS1
SSTYPStudy TypeGENOTOXICITY IN VITRO
32123MNTTS1
SSSTYPStudy Sub TypeIn Vitro Micronucleus
33123MNTTS1
SPECIESSpeciesHomo Sapiens
34123MNTTS1
??Test System?TK6 Lymphoblastoid Suspension Cells
35123NRUTS1
ASTDAssay StandardNIH Publication No. 07-4519
36123NRUTS1
ASTDVAssay Standard Version2006-11
37123NRUTS1
SSTYPStudy Type

38123NRUTS1
SSSTYPStudy Sub TypeIn Vitro Neutral Red Uptake
39123NRUTS1
SPECIESSpeciesHomo Sapiens

40

123NRUTS1
??Test System??Normal Human Keratinocyte
Expand
titletx.xpt (trial sets)

Treatment Duration will be controlled?  During CT definition/revies reviews will need to decide appropriate Treatment duration values; If not, what are best example values to show?For now, we just include good example values based on our experience

RowSTUDYIDASSAYIDDOMAINSETCDSETTXSEQTXPARMCDTXPARMTXVAL
1123MNTTXA1

METACTMetabolic ActivationActivation  (should there be two parms? Presence, type)?+S9
2123MNTTXA1

TRTDURTRTDRTRGTreatment Duration 3 - 6 target. (how do we show 3-6 hour range?  start/end, target and tolerance?, one text field not-analyzable)3

















TRTDRTOLTreatment Duration Tolerance







TRTDURUTreatment Duration Unit (this is for both TRTDURT, TRTDURTOL)TRTDURUH
3123MNTTXA1

PRDCONCConcentration of product0
4123MNTTXA1

PRDCONCUConcentration Unitug/ml
5123MNTTXA1

ProductProduct Name
6123MNTTXA1


Smoking Regime
7123MNTTXA1


Smoke Fraction

123MNTTXA2

METACTMetabolic Activation+S9

123MNTTXA2

TRTDURTreatment DurationShort Term

123MNTTXA2

PRDCONCConcentration of product1250

123MNTTXA2

PRDCONCUConcentration Unitug/ml

123MNTTXA2

ProductProduct Name

123MNTTXA2


Smoking Regime

123MNTTXA2


Smoke Fraction

123MNTTX

B1



METACTMetabolic Activation-S9

123MNTTX

B1



TRTDURTTRTDRTRGTreatment Duration target4 +/- 15m







TRTDURTOLTRTDRTOLTreatment Duration Tolerance.25
??123MNTTXB1

TRTDURUTreatment Duration Unit (this is for both TRTDURT, TRTDURTOL)H

123MNTTX

B1



PRDCONCConcentration of product0

123MNTTX

B1



PRDCONCUConcentration Unitug/ml

123MNTTXB1

ProductProduct Name

123MNTTXB1


Smoking Regime

123MNTTXB1


Smoke Fraction

123MNTTX

C1



METACTMetabolic Activation-S9

123MNTTX

C1



TRTDURTreatment Duration24
??123MNTTXC1

TRTDURUTreatment Duration UnitH

123MNTTX

C1



PRDCONCConcentration of product0

123MNTTX

C1



PRDCONCUConcentration Unitug/ml

123MNTTX

C1



ProductProduct Name

123MNTTXC1


Smoking Regime

123MNTTX

C1




Smoke Fraction

...